Subunit vaccines for the prevention of mucosal infection with Chlamydia trachomatis

References

• Progress report of the implementation of the global strategy for prevention and control of sexually transmitted infections: 2006–2015 [Internet]. World Health Organization; 2015. [cited 2016 Mar 15]. Available from: apps.who.int/iris/bitstream/10665/183117/1/9789241508841_eng.pdf?ua=1
   Google Scholar
• Sexually transmitted disease surveillance 2013. US Center for disease control [Internet]. Division of STD prevention; 2014. [cited 2016 Mar 15]. Available from: http://www.cdc.gov/std/stats13/
   Google Scholar
• Owusu-Edusei K Jr, Chesson HW, Gift TL, et al. The estimated direct medical cost of selected sexually transmitted infections in the United States, 2008. Sex Transm Dis. 2013;40(3):197–201.
   PubMed Web of Science ®Google Scholar
• Brunham RC, Gottlieb SL, Paavonen J. Pelvic inflammatory disease. N Engl J Med. 2015;372(21):2039–2048.
   PubMed Web of Science ®Google Scholar
• Brunham RC. Immunology. A Chlamydia vaccine on the horizon. Science. 2015;348(6241):1322–1323.
   PubMed Web of Science ®Google Scholar
• Brunham RC, Pourbohloul B, Mak S, et al. The unexpected impact of a Chlamydia trachomatis infection control program on susceptibility to reinfection. J Infect Dis. 2005;192(10):1836–1844.
   PubMed Web of Science ®Google Scholar
• Su H, Morrison R, Messer R, et al. The effect of doxycycline treatment on the development of protective immunity in a murine model of chlamydial genital infection. J Infect Dis. 1999;180(4):1252–1258.
   PubMed Web of Science ®Google Scholar
• Brunham RC, Rappuoli R. Chlamydia trachomatis control requires a vaccine. Vaccine. 2013;31(15):1892–1897.
   PubMed Web of Science ®Google Scholar
• Longbottom D. Chlamydial vaccine development. J Med Microbiol. 2003;52(Pt 7):537–540.
   PubMed Web of Science ®Google Scholar
• Grayston JT, Wang SP. The potential for vaccine against infection of the genital tract with Chlamydia trachomatis. Sex Transm Dis. 1978;5(2):73–77.
   PubMed Web of Science ®Google Scholar
• Wang SP, Grayston JT, Alexander ER. Trachoma vaccine studies in monkeys. Am J Ophthalmol. 1967;63(5 Suppl):1615–1630.
   PubMedGoogle Scholar
• Mabey DC, Hu V, Bailey RL, et al. Towards a safe and effective chlamydial vaccine: lessons from the eye. Vaccine. 2014;32(14):1572–1578.
   PubMed Web of Science ®Google Scholar
• Stephens RS, Kalman S, Lammel C, et al. Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis. Science. 1998;282(5389):754–759.
   PubMed Web of Science ®Google Scholar
• Read TD, Brunham RC, Shen C, et al. Genome sequences of Chlamydia trachomatis MoPn and Chlamydia pneumoniae AR39. Nucleic Acids Res. 2000;28(6):1397–1406.
   PubMed Web of Science ®Google Scholar
• Geisler WM. Duration of untreated, uncomplicated Chlamydia trachomatis genital infection and factors associated with chlamydia resolution: a review of human studies. J Infect Dis. 2010;201(Suppl 2):S104–113.
   PubMed Web of Science ®Google Scholar
• Batteiger BE, Xu F, Johnson RE, et al. Protective immunity to Chlamydia trachomatis genital infection: evidence from human studies. J Infect Dis. 2010;201(Suppl 2):S178–189.
   PubMed Web of Science ®Google Scholar
• Cohen CR, Koochesfahani KM, Meier AS, et al. Immunoepidemiologic profile of Chlamydia trachomatis infection: importance of heat-shock protein 60 and interferon- gamma. J Infect Dis. 2005;192(4):591–599.
   PubMed Web of Science ®Google Scholar
• Brunham RC, Kuo CC, Cles L, et al. Correlation of host immune response with quantitative recovery of Chlamydia trachomatis from the human endocervix. Infect Immun. 1983;39(3):1491–1494.
   PubMed Web of Science ®Google Scholar
• Igietseme JU. Molecular mechanism of T-cell control of Chlamydia in mice: role of nitric oxide in vivo. Immunology. 1996;88(1):1–5.
   PubMed Web of Science ®Google Scholar
• Igietseme JU. The molecular mechanism of T-cell control of Chlamydia in mice: role of nitric oxide. Immunology. 1996;87(1):1–8.
   PubMed Web of Science ®Google Scholar
• Igietseme JU, Uriri IM, Hawkins R, et al. Integrin-mediated epithelial-T cell interaction enhances nitric oxide production and increased intracellular inhibition of Chlamydia. J Leukoc Biol. 1996;59(5):656–662.
   PubMed Web of Science ®Google Scholar
• Yu H, Karunakaran KP, Kelly I, et al. Immunization with live and dead Chlamydia muridarum induces different levels of protective immunity in a murine genital tract model: correlation with MHC class II peptide presentation and multifunctional Th1 cells. J Immunology. 2011;186(6):3615–3621.
   PubMed Web of Science ®Google Scholar
• Johnson RM, Kerr MS, Slaven JE. Plac8-dependent and inducible NO synthase-dependent mechanisms clear Chlamydia muridarum infections from the genital tract. J Immunology. 2012;188(4):1896–1904.
   PubMed Web of Science ®Google Scholar
• Jayarapu K, Kerr M, Ofner S, et al. Chlamydia-specific CD4 T cell clones control Chlamydia muridarum replication in epithelial cells by nitric oxide-dependent and -independent mechanisms. J Immunology. 2010;185(11):6911–6920.
   PubMed Web of Science ®Google Scholar
• Igietseme JU, Perry LL, Ananaba GA, et al. Chlamydial infection in inducible nitric oxide synthase knockout mice. Infect Immun. 1998;66(4):1282–1286.
   PubMed Web of Science ®Google Scholar
• Morrison RP, Feilzer K, Tumas DB. Gene knockout mice establish a primary protective role for major histocompatibility complex class II-restricted responses in Chlamydia trachomatis genital tract infection. Infect Immun. 1995;63(12):4661–4668.
   PubMed Web of Science ®Google Scholar
• Morrison SG, Morrison RP. Resolution of secondary Chlamydia trachomatis genital tract infection in immune mice with depletion of both CD4+ and CD8+ T cells. Infect Immun. 2001;69(4):2643–2649.
   PubMed Web of Science ®Google Scholar
• Vlcek KR, Li W, Manam S, et al. The contribution of Chlamydia-specific CD8 T cells to upper genital tract pathology. Immunol Cell Biol. 2015;94(2):208–212.
   PubMed Web of Science ®Google Scholar
• Murthy AK, Li W, Chaganty BK, et al. Tumor necrosis factor alpha production from CD8+ T cells mediates oviduct pathological sequelae following primary genital Chlamydia muridarum infection. Infect Immun. 2011;79(7):2928–2935.
   PubMed Web of Science ®Google Scholar
• Igietseme JU, He Q, Joseph K, et al. Role of T lymphocytes in the pathogenesis of Chlamydia disease. J Infect Dis. 2009;200(6):926–934.
   PubMed Web of Science ®Google Scholar
• Igietseme JU, Magee DM, Williams DM, et al. Role for CD8+ T cells in antichlamydial immunity defined by Chlamydia-specific T-lymphocyte clones. Infect Immun. 1994;62(11):5195–5197.
   PubMed Web of Science ®Google Scholar
• Olivares-Zavaleta N, Whitmire WM, Kari L, et al. CD8+ T cells define an unexpected role in live-attenuated vaccine protective immunity against Chlamydia trachomatis infection in macaques. J Immunology. 2014;192(10):4648–4654.
   PubMed Web of Science ®Google Scholar
• Betts MR, Nason MC, West SM, et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood. 2006;107(12):4781–4789.
   PubMed Web of Science ®Google Scholar
• International HIVCS, Pereyra F, Jia X, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science. 2010;330(6010):1551–1557.
   PubMed Web of Science ®Google Scholar
• Kiviat NB, Wolner-Hanssen P, Eschenbach DA, et al. Endometrial histopathology in patients with culture-proved upper genital tract infection and laparoscopically diagnosed acute salpingitis. Am J Surg Pathol. 1990;14(2):167–175.
   PubMed Web of Science ®Google Scholar
• Morrison SG, Morrison RP. In situ analysis of the evolution of the primary immune response in murine Chlamydia trachomatis genital tract infection. Infect Immun. 2000;68(5):2870–2879.
   PubMed Web of Science ®Google Scholar
• Stary G, Olive A, Radovic-Moreno AF, et al. Vaccines. A mucosal vaccine against Chlamydia trachomatis generates two waves of protective memory T cells. Science. 2015;348(6241):aaa8205.
   PubMed Web of Science ®Google Scholar
• Li LX, McSorley SJ. A re-evaluation of the role of B cells in protective immunity to Chlamydia infection. Immunol Lett. 2015;164(2):88–93.
   PubMed Web of Science ®Google Scholar
• Su H, Feilzer K, Caldwell HD, et al. Chlamydia trachomatis genital tract infection of antibody-deficient gene knockout mice. Infect Immun. 1997;65(6):1993–1999.
   PubMed Web of Science ®Google Scholar
• Morrison SG, Su H, Caldwell HD, et al. Immunity to murine Chlamydia trachomatis genital tract reinfection involves B cells and CD4(+) T cells but not CD8(+) T cells. Infect Immun. 2000;68(12):6979–6987.
   PubMed Web of Science ®Google Scholar
• Morrison SG, Morrison RP. A predominant role for antibody in acquired immunity to chlamydial genital tract reinfection. J Immunology. 2005;175(11):7536–7542.
   PubMed Web of Science ®Google Scholar
• Rock KL, Benacerraf B, Abbas AK. Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors. J Exp Med. 1984;160(4):1102–1113.
   PubMed Web of Science ®Google Scholar
• Moore T, Ananaba GA, Bolier J, et al. Fc receptor regulation of protective immunity against Chlamydia trachomatis. Immunology. 2002;105(2):213–221.
   PubMed Web of Science ®Google Scholar
• Farris CM, Morrison SG, Morrison RP. CD4+ T cells and antibody are required for optimal major outer membrane protein vaccine-induced immunity to Chlamydia muridarum genital infection. Infect Immun. 2010;78(10):4374–4383.
   PubMed Web of Science ®Google Scholar
• Li LX, McSorley SJ. B cells enhance antigen-specific CD4 T cell priming and prevent bacteria dissemination following Chlamydia muridarum genital tract infection. PLoS Pathog. 2013;9(10):e1003707.
   Google Scholar
• De Clercq E, Kalmar I, Vanrompay D. Animal models for studying female genital tract infection with Chlamydia trachomatis. Infect Immun. 2013;81(9):3060–3067.
   PubMed Web of Science ®Google Scholar
• Morrison RP, Caldwell HD. Immunity to murine chlamydial genital infection. Infect Immun. 2002;70(6):2741–2751.
   PubMed Web of Science ®Google Scholar
• Farris CM, Morrison RP. Vaccination against Chlamydia genital infection utilizing the murine C. muridarum model. Infect Immun. 2011;79(3):986–996.
   PubMed Web of Science ®Google Scholar
• Molano M, Meijer CJ, Weiderpass E, et al. The natural course of Chlamydia trachomatis infection in asymptomatic Colombian women: a 5-year follow-up study. J Infect Dis. 2005;191(6):907–916.
   PubMed Web of Science ®Google Scholar
• Haggerty CL, Gottlieb SL, Taylor BD, et al. Risk of sequelae after Chlamydia trachomatis genital infection in women. J Infect Dis. 2010;201(Suppl 2):S134–155.
   PubMed Web of Science ®Google Scholar
• Sturdevant GL, Caldwell HD. Innate immunity is sufficient for the clearance of Chlamydia trachomatis from the female mouse genital tract. Pathog Dis. 2014;72(1):70–73.
   PubMed Web of Science ®Google Scholar
• Gondek DC, Olive AJ, Stary G, et al. CD4+ T cells are necessary and sufficient to confer protection against Chlamydia trachomatis infection in the murine upper genital tract. J Immunology. 2012;189(5):2441–2449.
   PubMed Web of Science ®Google Scholar
• Karunakaran KP, Yu H, Jiang X, et al. Outer membrane proteins preferentially load MHC class II peptides: implications for a Chlamydia trachomatis T cell vaccine. Vaccine. 2015;33(18):2159–2166.
   PubMed Web of Science ®Google Scholar
• Bell JD, Bergin IL, Schmidt K, et al. Nonhuman primate models used to study pelvic inflammatory disease caused by Chlamydia trachomatis. Infect Dis Obstet Gynecol. 2011;2011:675360.
   PubMedGoogle Scholar
• Qu Y, Frazer LC, O’Connell CM, et al. Comparable genital tract infection, pathology, and immunity in rhesus macaques inoculated with wild-type or plasmid-deficient chlamydia trachomatis Serovar D. Infect Immun. 2015;83(10):4056–4067.
   PubMed Web of Science ®Google Scholar
• O’Connell CM, AbdelRahman YM, Green E, et al. Toll-like receptor 2 activation by Chlamydia trachomatis is plasmid dependent, and plasmid-responsive chromosomal loci are coordinately regulated in response to glucose limitation by C. trachomatis but not by C. muridarum. Infect Immun. 2011;79(3):1044–1056.
   PubMed Web of Science ®Google Scholar
• Brunham RC, Rey-Ladino J. Immunology of Chlamydia infection: implications for a Chlamydia trachomatis vaccine. Nat Reviews Immunol. 2005;5(2):149–161.
   PubMed Web of Science ®Google Scholar
• Rappuoli R. Reverse vaccinology. Curr Opin Microbiol. 2000;3(5):445–450.
   PubMed Web of Science ®Google Scholar
• Finco O, Frigimelica E, Buricchi F, et al. Approach to discover T- and B-cell antigens of intracellular pathogens applied to the design of Chlamydia trachomatis vaccines. Proc Natl Acad Sci U S A. 2011;108(24):9969–9974.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang Y, Lu C, et al. A genome-wide profiling of the humoral immune response to Chlamydia trachomatis infection reveals vaccine candidate antigens expressed in humans. J Immunology. 2010;185(3):1670–1680.
   PubMed Web of Science ®Google Scholar
• Karunakaran KP, Rey-Ladino J, Stoynov N, et al. Immunoproteomic discovery of novel T cell antigens from the obligate intracellular pathogen Chlamydia. J Immunology. 2008;180(4):2459–2465.
   PubMed Web of Science ®Google Scholar
• Karunakaran KP, Yu H, Foster LJ, et al. Development of a Chlamydia trachomatis T cell Vaccine. Hum Vaccin. 2010;6(8):676–680.
   PubMed Web of Science ®Google Scholar
• Yu H, Jiang X, Shen C, et al. Chlamydia muridarum T-cell antigens formulated with the adjuvant DDA/TDB induce immunity against infection that correlates with a high frequency of gamma interferon (IFN-gamma)/tumor necrosis factor alpha and IFN-gamma/interleukin-17 double-positive CD4+ T cells. Infect Immun. 2010;78(5):2272–2282.
   PubMed Web of Science ®Google Scholar
• Becker E, Hegemann JH. All subtypes of the Pmp adhesin family are implicated in chlamydial virulence and show species-specific function. Microbiology Open. 2014;3(4):544–556.
   Web of Science ®Google Scholar
• Saka HA, Thompson JW, Chen YS, et al. Quantitative proteomics reveals metabolic and pathogenic properties of Chlamydia trachomatis developmental forms. Mol Microbiol. 2011;82(5):1185–1203.
   PubMed Web of Science ®Google Scholar
• Caldwell HD, Kromhout J, Schachter J. Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect Immun. 1981;31(3):1161–1176.
   PubMed Web of Science ®Google Scholar
• Yu H, Karunakaran KP, Jiang X, et al. Chlamydia muridarum T cell antigens and adjuvants that induce protective immunity in mice. Infect Immun. 2012;80(4):1510–1518.
   PubMed Web of Science ®Google Scholar
• Johnson RM, Yu H, Kerr MS, et al. PmpG303-311, a protective vaccine epitope that elicits persistent cellular immune responses in Chlamydia muridarum-immune mice. Infect Immun. 2012;80(6):2204–2211.
   PubMed Web of Science ®Google Scholar
• Yu H, Karunakaran KP, Jiang X, et al. Evaluation of a multisubunit recombinant polymorphic membrane protein and major outer membrane protein T cell vaccine against Chlamydia muridarum genital infection in three strains of mice. Vaccine. 2014;32(36):4672–4680.
   PubMed Web of Science ®Google Scholar
• Pal S, Theodor I, Peterson EM, et al. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. Infect Immun. 2001;69(10):6240–6247.
   PubMed Web of Science ®Google Scholar
• Olsen AW, Follmann F, Erneholm K, et al. Protection against chlamydia trachomatis infection and upper genital tract pathological changes by vaccine-promoted neutralizing antibodies directed to the VD4 of the major outer membrane protein. J Infect Dis. 2015;212(6):978–989.
   PubMed Web of Science ®Google Scholar
• Knudsen NP, Olsen A, Buonsanti C, et al. Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens. Sci Rep. 2016;6:19570.
   PubMed Web of Science ®Google Scholar
• De Veer M, Meeusen E. New developments in vaccine research–unveiling the secret of vaccine adjuvants. Discov Med. 2011;12(64):195–204.
   PubMed Web of Science ®Google Scholar
• Lee S, Nguyen MT. Recent advances of vaccine adjuvants for infectious diseases. Immune Netw. 2015;15(2):51–57.
   PubMed Web of Science ®Google Scholar
• Igietseme JU, Eko FO, Black CM. Chlamydia vaccines: recent developments and the role of adjuvants in future formulations. Expert Rev Vaccines. 2011;10(11):1585–1596.
   PubMed Web of Science ®Google Scholar
• Werninghaus K, Babiak A, Gross O, et al. Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation. J Exp Med. 2009;206(1):89–97.
   PubMed Web of Science ®Google Scholar
• Ishikawa E, Ishikawa T, Morita YS, et al. Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. J Exp Med. 2009;206(13):2879–2888.
   PubMed Web of Science ®Google Scholar
• Aagaard C, Hoang T, Dietrich J, et al. A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med. 2011;17(2):189–194.
   PubMed Web of Science ®Google Scholar
• Agger EM, Rosenkrands I, Hansen J, et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One. 2008;3(9):e3116.
   PubMed Web of Science ®Google Scholar
• van Dissel JT, Joosten SA, Hoff ST, et al. A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human. Vaccine. 2014;32(52):7098–7107.
   PubMed Web of Science ®Google Scholar
• Karlsson I, Brandt L, Vinner L, et al. Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection. Clin Immunology. 2013;146(2):120–130.
   PubMed Web of Science ®Google Scholar
• Nicholls EF, Madera L, Hancock RE. Immunomodulators as adjuvants for vaccines and antimicrobial therapy. Ann N Y Acad Sci. 2010;1213:46–61.
   PubMed Web of Science ®Google Scholar
• Newsted D, Fallahi F, Golshani A, et al. Advances and challenges in mucosal adjuvant technology. Vaccine. 2015;33(21):2399–2405.
   PubMed Web of Science ®Google Scholar
• McCluskie MJ, Weeratna RD, Davis HL. Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution. Mol Medicine. 2000;6(10):867–877.
   PubMed Web of Science ®Google Scholar
• Radovic-Moreno AF, Lu TK, Puscasu VA, et al. Surface charge-switching polymeric nanoparticles for bacterial cell wall-targeted delivery of antibiotics. ACS Nano. 2012;6(5):4279–4287.
   PubMed Web of Science ®Google Scholar
• Johnson RM, Brunham RC. Tissue resident T cells as the central paradigm of Chlamydia immunity. Infect Immun. 2016 Jan 19. doi:10.1128/IAI.01378-15. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Gray RT, Beagley KW, Timms P, et al. Modeling the impact of potential vaccines on epidemics of sexually transmitted Chlamydia trachomatis infection. J Infect Dis. 2009;199(11):1680–1688.
   PubMed Web of Science ®Google Scholar
• Owusu-Edusei K Jr, Chesson HW, Gift TL, et al. Cost-effectiveness of Chlamydia vaccination programs for young women. Emerg Infect Dis. 2015;21(6):960–968.
   PubMed Web of Science ®Google Scholar